首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   120838篇
  免费   8059篇
  国内免费   518篇
耳鼻咽喉   1310篇
儿科学   3617篇
妇产科学   2060篇
基础医学   16026篇
口腔科学   2178篇
临床医学   11921篇
内科学   25161篇
皮肤病学   1475篇
神经病学   11734篇
特种医学   3810篇
外国民族医学   1篇
外科学   17623篇
综合类   1641篇
一般理论   156篇
预防医学   10515篇
眼科学   3266篇
药学   8670篇
  1篇
中国医学   274篇
肿瘤学   7976篇
  2023年   560篇
  2022年   422篇
  2021年   1816篇
  2020年   1385篇
  2019年   2364篇
  2018年   2774篇
  2017年   2041篇
  2016年   2340篇
  2015年   2731篇
  2014年   3945篇
  2013年   5543篇
  2012年   8475篇
  2011年   9095篇
  2010年   4948篇
  2009年   4610篇
  2008年   8017篇
  2007年   8517篇
  2006年   8074篇
  2005年   8108篇
  2004年   7666篇
  2003年   7062篇
  2002年   6813篇
  2001年   1190篇
  2000年   879篇
  1999年   1147篇
  1998年   1235篇
  1997年   1008篇
  1996年   770篇
  1995年   915篇
  1994年   769篇
  1993年   770篇
  1992年   654篇
  1991年   616篇
  1990年   542篇
  1989年   502篇
  1988年   503篇
  1987年   479篇
  1986年   423篇
  1985年   501篇
  1984年   552篇
  1983年   511篇
  1982年   681篇
  1981年   589篇
  1980年   522篇
  1979年   361篇
  1978年   337篇
  1977年   337篇
  1976年   284篇
  1975年   259篇
  1974年   273篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
Thomas Behrens  Calvin Ge  Roel Vermeulen  Benjamin Kendzia  Ann Olsson  Joachim Schüz  Hans Kromhout  Beate Pesch  Susan Peters  Lützen Portengen  Per Gustavsson  Dario Mirabelli  Pascal Guénel  Danièle Luce  Dario Consonni  Neil E. Caporaso  Maria Teresa Landi  John K. Field  Stefan Karrasch  Heinz-Erich Wichmann  Jack Siemiatycki  Marie-Elise Parent  Lorenzo Richiardi  Lorenzo Simonato  Karl-Heinz Jöckel  Wolfgang Ahrens  Hermann Pohlabeln  Guillermo Fernández-Tardón  David Zaridze  John R. McLaughlin  Paul A. Demers  Beata Świątkowska  Jolanta Lissowska  Tamás Pándics  Eleonora Fabianova  Dana Mates  Vladimir Bencko  Lenka Foretova  Vladimír Janout  Paolo Boffetta  Bas Bueno-de-Mesquita  Francesco Forastiere  Kurt Straif  Thomas Brüning 《International journal of cancer. Journal international du cancer》2023,152(4):645-660
There is limited evidence regarding the exposure-effect relationship between lung-cancer risk and hexavalent chromium (Cr(VI)) or nickel. We estimated lung-cancer risks in relation to quantitative indices of occupational exposure to Cr(VI) and nickel and their interaction with smoking habits. We pooled 14 case-control studies from Europe and Canada, including 16 901 lung-cancer cases and 20 965 control subjects. A measurement-based job-exposure-matrix estimated job-year-region specific exposure levels to Cr(VI) and nickel, which were linked to the subjects' occupational histories. Odds ratios (OR) and associated 95% confidence intervals (CI) were calculated by unconditional logistic regression, adjusting for study, age group, smoking habits and exposure to other occupational lung carcinogens. Due to their high correlation, we refrained from mutually adjusting for Cr(VI) and nickel independently. In men, ORs for the highest quartile of cumulative exposure to CR(VI) were 1.32 (95% CI 1.19-1.47) and 1.29 (95% CI 1.15-1.45) in relation to nickel. Analogous results among women were: 1.04 (95% CI 0.48-2.24) and 1.29 (95% CI 0.60-2.86), respectively. In men, excess lung-cancer risks due to occupational Cr(VI) and nickel exposure were also observed in each stratum of never, former and current smokers. Joint effects of Cr(VI) and nickel with smoking were in general greater than additive, but not different from multiplicative. In summary, relatively low cumulative levels of occupational exposure to Cr(VI) and nickel were associated with increased ORs for lung cancer, particularly in men. However, we cannot rule out a combined classical measurement and Berkson-type of error structure, which may cause differential bias of risk estimates.  相似文献   
4.
Smoking cessation reduces the risk of death, improves recovery, and reduces the risk of hospital readmission. Evidence and policy support hospital admission as an ideal time to deliver smoking-cessation interventions. However, this is not well implemented in practice. In this systematic review, the authors summarize the literature on smoking-cessation implementation strategies and evaluate their success to guide the implementation of best-practice smoking interventions into hospital settings. The CINAHL Complete, Embase, MEDLINE Complete, and PsycInfo databases were searched using terms associated with the following topics: smoking cessation, hospitals, and implementation. In total, 14,287 original records were identified and screened, resulting in 63 eligible articles from 56 studies. Data were extracted on the study characteristics, implementation strategies, and implementation outcomes. Implementation outcomes were guided by Proctor and colleagues' framework and included acceptability, adoption, appropriateness, cost, feasibility, fidelity, penetration, and sustainability. The findings demonstrate that studies predominantly focused on the training of staff to achieve implementation. Brief implementation approaches using a small number of implementation strategies were less successful and poorly sustained compared with well resourced and multicomponent approaches. Although brief implementation approaches may be viewed as advantageous because they are less resource-intensive, their capacity to change practice in a sustained way lacks evidence. Attempts to change clinician behavior or introduce new models of care are challenging in a short time frame, and implementation efforts should be designed for long-term success. There is a need to embrace strategic, well planned implementation approaches to embed smoking-cessation interventions into hospitals and to reap and sustain the benefits for people who smoke.  相似文献   
5.
The European Journal of Health Economics - Phenylketonuria (PKU) is a metabolic disorder leading to a deficiency in the metabolism of phenylalanine (Phe). Elevated Phe levels in the blood, tissue...  相似文献   
6.
Ecotoxicology - Eutrophication of water bodies and deterioration of water quality are emerging environmental crises. The root causes and consequences of eutrophication are multidirectional. Thus,...  相似文献   
7.
Journal of Thrombosis and Thrombolysis - Early prediction of significant morbidity or mortality in patients with acute ST-segment elevation myocardial infarction (STEMI) represents an unmet...  相似文献   
8.
Journal of Digital Imaging - The purpose of this study was to evaluate the feasibility of translation of RadLex lexicon from English to German performed by Google Translate, using the RadLex...  相似文献   
9.
Background

Vaccination prevents severe morbidity and mortality from COVID-19 in the general population. The immunogenicity and efficacy of SARS-CoV-2 vaccines in patients with antibody deficiency is poorly understood.

Objectives

COVID-19 in patients with antibody deficiency (COV-AD) is a multi-site UK study that aims to determine the immune response to SARS-CoV-2 infection and vaccination in patients with primary or secondary antibody deficiency, a population that suffers from severe and recurrent infection and does not respond well to vaccination.

Methods

Individuals on immunoglobulin replacement therapy or with an IgG less than 4 g/L receiving antibiotic prophylaxis were recruited from April 2021. Serological and cellular responses were determined using ELISA, live-virus neutralisation and interferon gamma release assays. SARS-CoV-2 infection and clearance were determined by PCR from serial nasopharyngeal swabs.

Results

A total of 5.6% (n?=?320) of the cohort reported prior SARS-CoV-2 infection, but only 0.3% remained PCR positive on study entry. Seropositivity, following two doses of SARS-CoV-2 vaccination, was 54.8% (n?=?168) compared with 100% of healthy controls (n?=?205). The magnitude of the antibody response and its neutralising capacity were both significantly reduced compared to controls. Participants vaccinated with the Pfizer/BioNTech vaccine were more likely to be seropositive (65.7% vs. 48.0%, p?=?0.03) and have higher antibody levels compared with the AstraZeneca vaccine (IgGAM ratio 3.73 vs. 2.39, p?=?0.0003). T cell responses post vaccination was demonstrable in 46.2% of participants and were associated with better antibody responses but there was no difference between the two vaccines. Eleven vaccine-breakthrough infections have occurred to date, 10 of them in recipients of the AstraZeneca vaccine.

Conclusion

SARS-CoV-2 vaccines demonstrate reduced immunogenicity in patients with antibody deficiency with evidence of vaccine breakthrough infection.

  相似文献   
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号